White Paper - Liquid Biopsies for Lung Cancer: Vision 2020
Liquid biopsies are non-invasive tests, most commonly blood-based, that detect cancer through the identification of shed genetic material into circulation. The technology holds the promise of a non-invasive ‘Swiss army knife’ of diagnostics, with the potential for utility across screening, diagnosis, monitoring, treatment selection, and resistance detection to spare patients unnecessary procedures.

Although liquid biopsies encompass a range of possible targets including circulating tumor DNA (ctDNA), circulating tumor cells and exosomes, ctDNA liquid biopsies have been most swiftly adopted in clinical practice. Its utility has been most evident in non-small cell lung cancer (NSCLC).

This white paper will concisely describe Lucence Diagnostics' perspective on ctDNA liquid biopsies in NSCLC in 2020. As a global liquid biopsy service laboratory with operations both in Asia (where 40-50% of NSCLC have EGFR mutation) and the United States (where 10% of NSCLC have EGFR mutation), our shared experience can contribute to wider understanding and advancement of the field.

Please complete this form to download the white paper.

Email address *
Full Name *
Your answer
Organization *
Your answer
Never submit passwords through Google Forms.
This form was created inside of Lucence Diagnostics Pte Ltd. Report Abuse - Terms of Service